|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM258517638 |
003 |
DE-627 |
005 |
20231224185158.0 |
007 |
cr uuu---uuuuu |
008 |
231224s2016 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1021/acs.langmuir.6b00511
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0861.xml
|
035 |
|
|
|a (DE-627)NLM258517638
|
035 |
|
|
|a (NLM)26987014
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Noyhouzer, Tomer
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Ferrocene-Modified Phospholipid
|b An Innovative Precursor for Redox-Triggered Drug Delivery Vesicles Selective to Cancer Cells
|
264 |
|
1 |
|c 2016
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 29.05.2018
|
500 |
|
|
|a Date Revised 31.03.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Controlled payload release is one of the key elements in the creation of a reliable drug delivery system. We report the discovery of a drug delivery vessel able to transport chemotherapeutic agents to target cancer cells and selectively trigger their release using the electrochemical activity of a ferrocene-modified phospholipid. Supported by in vitro assays, the competitive advantages of this discovery are (i) the simple one step scalability of the synthetic process, (ii) the stable encapsulation of toxic drugs (doxorubicin) during transport, and (iii) the selective redox triggering of the liposomes to harness their cytotoxic payload at the cancer site. Specifically, the redox-modified giant unilamellar vesicle and liposomes were characterized using advanced methods such as scanning electrochemical microscopy (SECM), transmission electron microscopy (TEM), dynamic light scattering (DLS), and fluorescent imaging
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Drug Carriers
|2 NLM
|
650 |
|
7 |
|a Ferrous Compounds
|2 NLM
|
650 |
|
7 |
|a Metallocenes
|2 NLM
|
650 |
|
7 |
|a Phospholipids
|2 NLM
|
650 |
|
7 |
|a Doxorubicin
|2 NLM
|
650 |
|
7 |
|a 80168379AG
|2 NLM
|
650 |
|
7 |
|a ferrocene
|2 NLM
|
650 |
|
7 |
|a U96PKG90JQ
|2 NLM
|
700 |
1 |
|
|a L'Homme, Chloé
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Beaulieu, Isabelle
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Mazurkiewicz, Stephanie
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kuss, Sabine
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kraatz, Heinz-Bernhard
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Canesi, Sylvain
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Mauzeroll, Janine
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1999
|g 32(2016), 17 vom: 03. Mai, Seite 4169-78
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
773 |
1 |
8 |
|g volume:32
|g year:2016
|g number:17
|g day:03
|g month:05
|g pages:4169-78
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.6b00511
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_721
|
951 |
|
|
|a AR
|
952 |
|
|
|d 32
|j 2016
|e 17
|b 03
|c 05
|h 4169-78
|